Logo image of ASXC

Asensus Surgical Inc (ASXC) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:ASXC - US04367G1031 - Common Stock

0.3479 USD
+0 (+0.64%)
Last: 8/21/2024, 8:05:47 PM
0.3487 USD
+0 (+0.23%)
After Hours: 8/21/2024, 8:05:47 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ASXC. ASXC was compared to 188 industry peers in the Health Care Equipment & Supplies industry. While ASXC seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ASXC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ASXC has reported negative net income.
ASXC had a negative operating cash flow in the past year.
In the past 5 years ASXC always reported negative net income.
ASXC had a negative operating cash flow in each of the past 5 years.
ASXC Yearly Net Income VS EBIT VS OCF VS FCFASXC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -192.86%, ASXC is not doing good in the industry: 93.72% of the companies in the same industry are doing better.
ASXC's Return On Equity of -604.36% is on the low side compared to the rest of the industry. ASXC is outperformed by 89.53% of its industry peers.
Industry RankSector Rank
ROA -192.86%
ROE -604.36%
ROIC N/A
ROA(3y)-77.11%
ROA(5y)-102.82%
ROE(3y)-115.84%
ROE(5y)-144.56%
ROIC(3y)N/A
ROIC(5y)N/A
ASXC Yearly ROA, ROE, ROICASXC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ASXC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASXC Yearly Profit, Operating, Gross MarginsASXC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

4

2. Health

2.1 Basic Checks

ASXC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASXC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ASXC has been increased compared to 5 years ago.
ASXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ASXC Yearly Shares OutstandingASXC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
ASXC Yearly Total Debt VS Total AssetsASXC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -37.31, we must say that ASXC is in the distress zone and has some risk of bankruptcy.
ASXC has a Altman-Z score of -37.31. This is amonst the worse of the industry: ASXC underperforms 93.19% of its industry peers.
There is no outstanding debt for ASXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.31
ROIC/WACCN/A
WACC8.7%
ASXC Yearly LT Debt VS Equity VS FCFASXC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.00 indicates that ASXC may have some problems paying its short term obligations.
ASXC's Current ratio of 1.00 is on the low side compared to the rest of the industry. ASXC is outperformed by 92.67% of its industry peers.
A Quick Ratio of 0.69 indicates that ASXC may have some problems paying its short term obligations.
With a Quick ratio value of 0.69, ASXC is not doing good in the industry: 92.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1
Quick Ratio 0.69
ASXC Yearly Current Assets VS Current LiabilitesASXC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.65% over the past year.
ASXC shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.97%.
The Revenue for ASXC have been decreasing by -18.67% on average. This is quite bad
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)20.97%
Revenue growth 3Y39.2%
Revenue growth 5Y-18.67%
Sales Q2Q%104.44%

3.2 Future

ASXC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.08% yearly.
ASXC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 79.22% yearly.
EPS Next Y21.03%
EPS Next 2Y17.25%
EPS Next 3Y20.2%
EPS Next 5Y19.08%
Revenue Next Year43.58%
Revenue Next 2Y61.51%
Revenue Next 3Y82.88%
Revenue Next 5Y79.22%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ASXC Yearly Revenue VS EstimatesASXC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ASXC Yearly EPS VS EstimatesASXC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ASXC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASXC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASXC Price Earnings VS Forward Price EarningsASXC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASXC Per share dataASXC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as ASXC's earnings are expected to grow with 20.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.25%
EPS Next 3Y20.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASXC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Asensus Surgical Inc

NYSEARCA:ASXC (8/21/2024, 8:05:47 PM)

After market: 0.3487 +0 (+0.23%)

0.3479

+0 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-13 2024-08-13/amc
Earnings (Next)11-12 2024-11-12/amc
Inst Owners0.02%
Inst Owner Change0%
Ins Owners0.13%
Ins Owner Change0%
Market Cap94.62M
Revenue(TTM)8.58M
Net Income(TTM)-78.71M
Analysts45.71
Price Target0.36 (3.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.2%
Min EPS beat(2)-56.86%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)-9.68%
Min EPS beat(4)-56.86%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)-7.14%
EPS beat(12)8
Avg EPS beat(12)-2.75%
EPS beat(16)12
Avg EPS beat(16)6.09%
Revenue beat(2)1
Avg Revenue beat(2)-3.78%
Min Revenue beat(2)-8.03%
Max Revenue beat(2)0.46%
Revenue beat(4)1
Avg Revenue beat(4)-13.71%
Min Revenue beat(4)-46.28%
Max Revenue beat(4)0.46%
Revenue beat(8)1
Avg Revenue beat(8)-18.28%
Revenue beat(12)3
Avg Revenue beat(12)1.25%
Revenue beat(16)7
Avg Revenue beat(16)7.58%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.87
P/FCF N/A
P/OCF N/A
P/B 7.28
P/tB 7.96
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0.03
BVpS0.05
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -192.86%
ROE -604.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-77.11%
ROA(5y)-102.82%
ROE(3y)-115.84%
ROE(5y)-144.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.31%
Cap/Sales 5.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1
Quick Ratio 0.69
Altman-Z -37.31
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)12.1%
Cap/Depr(5y)7.97%
Cap/Sales(3y)13.75%
Cap/Sales(5y)9.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y21.03%
EPS Next 2Y17.25%
EPS Next 3Y20.2%
EPS Next 5Y19.08%
Revenue 1Y (TTM)20.97%
Revenue growth 3Y39.2%
Revenue growth 5Y-18.67%
Sales Q2Q%104.44%
Revenue Next Year43.58%
Revenue Next 2Y61.51%
Revenue Next 3Y82.88%
Revenue Next 5Y79.22%
EBIT growth 1Y-4.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.25%
OCF growth 3YN/A
OCF growth 5YN/A

Asensus Surgical Inc / ASXC FAQ

What is the fundamental rating for ASXC stock?

ChartMill assigns a fundamental rating of 2 / 10 to ASXC.


Can you provide the valuation status for Asensus Surgical Inc?

ChartMill assigns a valuation rating of 1 / 10 to Asensus Surgical Inc (ASXC). This can be considered as Overvalued.


How profitable is Asensus Surgical Inc (ASXC) stock?

Asensus Surgical Inc (ASXC) has a profitability rating of 0 / 10.


What is the earnings growth outlook for Asensus Surgical Inc?

The Earnings per Share (EPS) of Asensus Surgical Inc (ASXC) is expected to grow by 21.03% in the next year.